Evidence map›Paper›PMID 37814150›Full record

ArticleUpdates in surgery2024

Characteristics and outcomes of rectal cancer in patients with inflammatory bowel disease: a single-center experience.

Sameh Hany Emile, Nir Horesh, Zoe Garoufalia, Peter Rogers, Rachel Gefen, Giovanna Dasilva, Steven D Wexner

Abstract read
PubMed Publisher
In one paragraph

Article in Updates in surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Sameh Hany EmileEllen Leifer Shulman and Steven Shulman Digestive Disease, Cleveland Clinic Florida, Center, 2950 Cleveland Clinic Blvd, Weston, FL, 33331, USA.
Nir HoreshEllen Leifer Shulman and Steven Shulman Digestive Disease, Cleveland Clinic Florida, Center, 2950 Cleveland Clinic Blvd, Weston, FL, 33331, USA.
Zoe GaroufaliaEllen Leifer Shulman and Steven Shulman Digestive Disease, Cleveland Clinic Florida, Center, 2950 Cleveland Clinic Blvd, Weston, FL, 33331, USA.
Peter RogersEllen Leifer Shulman and Steven Shulman Digestive Disease, Cleveland Clinic Florida, Center, 2950 Cleveland Clinic Blvd, Weston, FL, 33331, USA.
Rachel GefenEllen Leifer Shulman and Steven Shulman Digestive Disease, Cleveland Clinic Florida, Center, 2950 Cleveland Clinic Blvd, Weston, FL, 33331, USA.
Giovanna DasilvaEllen Leifer Shulman and Steven Shulman Digestive Disease, Cleveland Clinic Florida, Center, 2950 Cleveland Clinic Blvd, Weston, FL, 33331, USA.
Steven D WexnerEllen Leifer Shulman and Steven Shulman Digestive Disease, Cleveland Clinic Florida, Center, 2950 Cleveland Clinic Blvd, Weston, FL, 33331, USA. wexners@ccf.org.ORCID http://orcid.org/0000-0001-8046-5753
Cleveland Clinic Florida · USHebrew University of Jerusalem · ILMansoura University Hospital · EGSheba Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increased risk of colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) has been well documented in the literature. The present study aimed to assess the characteristics and outcomes of rectal cancer in patients with IBD. This study was a retrospective review of a prospectively maintained IRB-approved database at Cleveland Clinic Florida. Rectal cancer patients with or without IBD treated with curative surgery between 2016 and 2020 were compared for demographics, disease characteristics, and pathologic and oncologic outcomes. The primary outcomes were 3-year overall survival (OS) and disease-free survival (DFS). Secondary outcomes were clinicopathologic outcomes including disease stage, tumor histology and histologic features, and treatments received. 238 patients with rectal cancer were included, 15 (6.3%) of whom had IBD. IBD patients were significantly younger (52.9 vs 60.3 years, p = 0.033), presented more often with cT1-2 tumors (64.3% vs 30.4%, p = 0.008), and signet-ring cell pathology (14.3% vs 2%, p = 0.02). IBD patients received neoadjuvant chemoradiation less often (40% vs 72.6%, p = 0.029) and had shorter time between diagnosis and surgery (7.5 vs 25 weeks, p = 0.013) than did non-IBD patients. Both groups had similar OS (36 vs 34.7 months, p = 0.431) and DFS (36 vs 32.9 months, p = 0.121). IBD patients with rectal cancer tend to present at a younger age, with a less invasive disease, and signet-ring carcinomas, and receive neoadjuvant treatment less often than non-IBD patients. Based on low level of evidence, IBD and non-IBD rectal cancer patients might have similar survival.

Indexed as

Carcinoma, Signet Ring CellInflammatory Bowel DiseasesRectal NeoplasmsDisease-Free SurvivalHumansNeoadjuvant TherapyNeoplasm StagingRetrospective StudiesCharacteristicsInflammatory bowel diseaseOutcomesRectal cancerSingle-center

Identifiers

PMID37814150
OpenAlexW4387449565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.